Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Milind M. Javle

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9158-0941; OpenAlex author ID A5054771911, A5065474995; NIH RePORTER profile ID 9201755. Sources: ClinicalTrials.gov.

Their work

Papers
57 (first author 2, last author 3)
Trials
5 (principal investigator on 4)
Grants
1
Labs led
1
Collaborators
190
Papers, trials and grants by year

2008: 2 trials · 2009: none · 2010: none · 2011: 5 papers, 1 grant · 2012: 1 paper · 2013: 1 paper · 2014: 7 papers · 2015: 3 papers, 1 trial · 2016: 7 papers, 1 trial · 2017: 7 papers · 2018: 5 papers · 2019: 3 papers, 1 trial · 2020: 7 papers · 2021: 5 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 50 of 57

  1. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-3189↗
  2. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
  3. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  4. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  5. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-21-1248↗
  6. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  7. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Pha… Co-author DOI 10.1001/jamaoncol.2021.0006↗
  8. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  9. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s10637-020-01000-6↗
  10. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  11. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Co-author DOI 10.21037/jgo-20-569↗
  12. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  13. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
  14. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
  15. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  16. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. First author DOI 10.1136/jitc-2020-000587↗
  17. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0224↗
  18. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. Co-author DOI 10.21037/jgo.2019.10.05↗
  19. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2018.09.022↗
  20. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  21. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
  22. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
  23. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx542↗
  24. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  25. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12967-018-1677-2↗
  26. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic… Last author DOI 10.1186/s13045-018-0616-2↗
  27. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2017.2227↗
  28. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  29. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Co-author DOI 10.1016/j.ijrobp.2016.10.046↗
  30. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Co-author DOI 10.1038/bjc.2017.19↗
  31. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗
  32. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Co-author DOI 10.18632/oncotarget.19897↗
  33. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. First author DOI 10.6004/jnccn.2017.0133↗
  34. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.30117↗
  35. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  36. Changing the course of pancreatic cancer--Focus on recent translational advances. Co-author DOI 10.1016/j.ctrv.2016.01.004↗
  37. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolida… Co-author DOI 10.1016/j.ijrobp.2015.12.003↗
  38. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.molonc.2015.11.012↗
  39. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5561↗
  40. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0156910↗
  41. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2788-6↗
  42. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Co-author DOI 10.1245/s10434-015-4854-z↗
  43. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Co-author DOI 10.3109/0284186x.2014.1000466↗
  44. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? Last author DOI 10.1007/s13539-014-0145-y↗
  45. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Last author DOI 10.1016/j.clon.2014.06.002↗
  46. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Co-author DOI 10.1088/1478-3975/11/6/065002↗
  47. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-con… Co-author DOI 10.1097/mpa.0000000000000095↗
  48. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Co-author DOI 10.1172/jci73455↗
  49. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0085942↗
  50. Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicente… Co-author DOI 10.3978/j.issn.2078-6891.2014.070↗

Trials 5

  1. Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer Principal investigator NCT03432676↗
  2. Olaparib in Treating Patients With Stage IV Pancreatic Cancer Principal investigator NCT02677038↗
  3. C-VISA BikDD: Liposome in Advanced Pancreatic Cancer Study chair NCT00968604↗
  4. Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer Principal investigator NCT00640978↗
  5. MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer Principal investigator NCT00769483↗

Grants 1

  1. Phase I Study of the BikDD Nanoparticle for Advanced Cancer of the Pancreas R21CA135604↗

Closest collaborators

The 25 strongest of 190 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert A. Wolff · 40 shared papers, 2011–2024 · strength 2.80
  2. Gauri Rajani Varadhachary · 32 shared papers, 2011–2022 · strength 2.01
  3. Matthew H. G. Katz · 28 shared papers, 2011–2023 · strength 1.88
  4. Michael James Overman · 20 shared papers, 2013–2024 · strength 1.71
  5. David R. Fogelman · 23 shared papers, 2011–2021 · strength 1.57
  6. Shubham Pant · 13 shared papers, 2020–2024 · strength 1.46
  7. Ching-Wei David Tzeng · 12 shared papers, 2015–2024 · strength 1.22
  8. Jeffrey E. Lee · 18 shared papers, 2011–2023 · strength 1.20
  9. Michael P. Kim · 13 shared papers, 2016–2023 · strength 1.14
  10. Rachna T. Shroff · 16 shared papers, 2014–2021 · strength 1.14
  11. Laura R. Prakash · 13 shared papers, 2016–2023 · strength 1.06
  12. Eugene Jon Koay · 15 shared papers, 2014–2023 · strength 1.05
  13. Anirban Maitra · 14 shared papers, 2014–2022 · strength 0.92
  14. Huamin Wang · 14 shared papers, 2014–2023 · strength 0.89
  15. Jason B. Fleming · 18 shared papers, 2011–2019 · strength 0.78
  16. Christopher H. Crane · 16 shared papers, 2011–2022 · strength 0.75
  17. Naruhiko Ikoma · 6 shared papers, 2020–2023 · strength 0.67
  18. Talia Golan · 5 shared papers, 2016–2026 · strength 0.65
  19. Priya Bhosale · 9 shared papers, 2014–2022 · strength 0.60
  20. Jonathan D. Mizrahi · 5 shared papers, 2020–2021 · strength 0.55
  21. Jane Elizabeth Rogers · 5 shared papers, 2020–2021 · strength 0.55
  22. Sunil Krishnan · 10 shared papers, 2011–2022 · strength 0.52
  23. Joseph M. Herman · 6 shared papers, 2016–2021 · strength 0.46
  24. Giampaolo Perri · 4 shared papers, 2020–2022 · strength 0.43
  25. Eric Peter Tamm · 7 shared papers, 2014–2022 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.